Status:
UNKNOWN
Balanced Crystalloid Solutions for Acute Pancreatitis
Lead Sponsor:
University Hospital Rijeka
Collaborating Sponsors:
University of Rijeka
Conditions:
Acute Pancreatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients diagnosed with acute pancreatitis regardless of etiology, severity of disease, and prior attacks will be randomized in two groups. The intervention group will receive a balanced crystalloid (...
Eligibility Criteria
Inclusion
- \- patients diagnosed with acute pancreatitis based on the revised Atlanta criteria who present to our hospital within 48 hours of symptoms onset, regardless of etiology, severity of disease, or prior episodes of acute pancreatitis
Exclusion
- chronic pancreatitis
- liver cirrhosis (Child-Pugh B and C)
- chronic hearth failure (NYHA\>II)
- acute coronary syndrome
- cardiovascular intervention within 60 days before randomization
- chronic obstructive pulmonary disease dependent of home oxygenator or acute exacerbation of chronic obstructive pulmonary disease
- chronic kidney disease (eGFR \<30 ml/min/1.73 m2)
- concomitant biliary infection (cholecystitis, cholangitis)
- severe autoimmune disease
- chronic active infection (TBC, AIDS)
- metastatic malignant disease
- primary pancreatic neoplasm
- patients transferred from other hospitals
- pregnancy and ongoing breastfeeding
- not willing to participate
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT04688645
Start Date
May 1 2020
End Date
February 1 2023
Last Update
December 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Rijeka
Rijeka, Croatia, 51000